Spherics has developed advanced oral systems based on the application of proprietary bioadhesive polymers to oral dosage forms. These broadly enabling technologies have potential to expand the therapeutic benefits of drugs that otherwise do not remain at the target absorptive site long enough to be effective or have issues of low bioavailability when administered systemically.
The benefits of the company’s technologies include improving efficacy, reducing side effects, providing more consistent drug levels and enhancing compliance.
“We are very excited to be working on improving the attributes of this Takeda product,” said Dr Ze’ev Shaked, president and CEO of Spherics. “The Takeda agreement confirms the potential of our oral bioadhesive delivery technologies to enhance the pharmacokinetic and pharmacodynamic properties of compounds under development within the pipelines of leading global pharmaceutical firms.”
Terms of the agreement were not disclosed.